Eli Lilly's recently recalled glucagon kits were produced at troubled Indianapolis site — report
Days after it was revealed that Eli Lilly’s diabetes injection kit had been recalled after a report of a mixup of glucagon substance, Reuters has reported the kits were manufactured in the Indianapolis plant called out in a Form 483.
On Sept. 24, the kit was recalled after liquid glucagon replaced the powdered version in the kit, which could fail to treat severe low blood sugar, due to a loss of potency. If not reversed, extreme low blood sugar can lead to neurological damage, seizures, and death. One lot, D239382D with an expiration date of April 2022, has been recalled, and the company issued a recall the following day.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
